Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/macrophage-colony-stimulating-factor-gene-encoded vaccinia virus

Journal of Cancer Research and Clinical Oncology

Volumn 122, Issue 12, 1996, Pages 716-722

  Ju, Dian Wen ^a   Cao, Xuetao ^a   Acres, Bruce ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b TRANSGENE S A   (France)

Author keywords

gene therapy; GM CSF; macrophage; melanoma; metastasis; recombinant vaccinia virus

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VACCINIA ONCOLYSATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; GENE THERAPY; LUNG METASTASIS; MACROPHAGE ACTIVATION; MALE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 0029849174     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01209118     Document Type: Article

References (31)

1. Abe J, Wakimoto H, Nakamura Y, et al. (1994) Immunogene therapy for cancer by cytokine gene-modified tumor vaccine and tumor-infiltrating lymphocytes (TIL). Cancer Gene Ther 1:312
2. Abe J, Wakimoto H, Yoshida Y, et al. (1995) Antitumor effect induced by granulocyte/macrophage-colony-stimulating-factor-gene-modified tumor vaccination: comparison of adenovirus-and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 121:587-592
3. Acres B, Dott K, Stefani L, Kieny MP (1994) Directed cytokine expression in tumor cells in vivo using recombinant vaccinia virus. Ther Immunol 1:17-23
4. Anderson WF (1994) Gene therapy for cancer. Hum Gene Ther 5:1-2
5. Arroyo PJ, Bash JA, Wallack MK (1990) Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon γ in a murine hepatic metastasis model. Cancer Immunol Immunother 31:305-311
6. Asher AL, Mule JJ, Kasid A, et al. (1991) Murine tumor cells transduced with the gene for tumor necrosis factor-α. J Immunol 146:3227-3234
7. Bash JA (1993) Recombinant vaccinia virus interleukin-2-infected tumor cell vaccines in immunotherapy of murine colon adenocarcinoma. J Immunother 1:269-272
8. Cao X, Zhang W, Yu Y, et al. (1995) Induction of antitumor immunity and treatment of preestablished tumors by inactivated IL-6 gene transfected melanoma cells combined with low dose IL-2. J Cancer Res Clin Oncol 121:721-728
9. Cao X, Chen G, Zhang W, et al. (1996) Enhanced efficacy of combination of IL-2 gene and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors. Gene Ther 3:421-426
10. Ding AH, Nathan CF, Stueher DJ (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediated from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol 141:2407-2412
11. Dranoff G, Jaffee E, Lazenby A, et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte/macrophage-colony-stimulating factor stimulates potent, specific and long lasting antitumor immunity. Proc Natl Acad Sci USA 90:3539-3543
12. Elkins KL, Ennist DL, Winegar RT, Weir JP (1994) In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice. Hum Gene Ther 5:809-820
13. Flexner C, Hugin A, Moss B, et al. (1987) Prevention of vaccinia virus infection in immunodeficient mice by vector-derived IL-2 expression. Nature 330:259-262
14. Foon KA (1989) Biological response modifiers: the new immunotherapy. Cancer Res 49:1621-1639
15. Gansbacher B, Bannerji R, Daniels B, et al. (1990) Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820-7825
16. Hersey P, Edwards A, Coats A, Shaw H, MaCarthy WH, Milton GW (1987) Evidence with treatment with vaccinia melanoma cell lysate (VMCL) may improve survival of patients with stage II melanoma patients. Cancer Immunol Immunother 25:257-265
17. Iwaki H, Barnavon Y, Bash JA, Wallack MK (1989) Vaccinia-virus infected CC-36 colon tumor lysates stimulate cellular response in vitro and protect syngeneic Balb/c mice from tumor cell challenge. J Surg Oncol 40:9-14
18. Ju DW, Zheng QY, Wang HB, et al. (1993) Effect of platelet activating factor antagonist WEB 2086 on the production of TNF from murine peritoneal macrophages. Acta Pharm Sin 28:721-727
19. Ju DW, Zheng QY, Wang HB, et al. (1994) Inhibitory effects of triazolodiazepine on mouse splenocytes and peritoneal macrophages in vitro. Acta Pharmacol Sin 15:65-68
20. Loosdrecht AA, van de Nennie E, Ossenkoppele GJ, et al. (1991) Cell mediated cytotoxicity against U937 cells by human monocytes and macrophages in a modified colometric MTT assay. J Immunol Methods 141:15-22
21. Mackett M, Smith GL, Moss B (1982) Vaccinia virus: a selectable eukaryotic cloning and expressing vector. Proc Natl Acad Sci USA 79:7415-7419
22. McCabe BJ, Irvine KR, Nishimura MI, et al. (1995) Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte response. Cancer Res 55:1741-1747
23. Moss B (1991) Vaccinia virus: a tool for research and vaccine development. Science 252:1662-1667
24. Mullbacher A, Ramshaw IA, Coupar BEH (1989) Vaccinia-interleukin 2 recombinant virus or exogenous interleukin 2 does not alter the magnitude or immune response gene defects of the cytotoxic T-cell response to vaccinia virus in vivo. Scand J Immunol 29:1-6
25. Porgador A, Bannerji R, Watanube Y, et al. (1993) Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J Immunol 150:1458-1470
26. Ram Z, Culver KM, Walbridge S, et al. (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53:83-88
27. Ramshaw I, Ruby J, Ramsay A, et al. (1992) Expression ofcytokines by recombinant vaccinia virus: a model for studying cytokines in virus infection in vivo. Immunol Rev 127:157-182
28. Sivanandham M, Scoggin SD, Tanaka N, Wallack MK (1994) Therapeutic effect of a vaccinia colon oneolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model. Cancer Immunol Immunother 38:259-264
29. Wallack MK (1982) Specific tumor immunity produced by the injection of vaccinia viral oncolysates. J Surg Res 33:11-16
30. Whitamn ED, Tsung K, Paxson J, Norton JA (1994) In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery 116:183-188
31. Yu Y, Cao X, Xu Z, et al. (1995) Combined therapeutic effects of IL-2 gene and IL-4 gene transfected tumor vaccines on pulmonary metastatic melanoma and its immunological mechanisms. Chin J Microbiol Immunol 15:397-401